Drug Trial Radar · NCT05248672
Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Feb 15, 2022
Primary completion
Jun 1, 2022
Study completion Jun 1, 2022
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.
Conditions
- Alzheimer Disease
Interventions
CT1812Drug
Study Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in plasmaTime frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF).Time frame: Day 13 and 15.
- Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF)- CSF/plasma ratioTime frame: Day 13 and 15.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Accel Clinical Research
DeLand, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.